This mutation has been reported in approximately 50% of patients with acquired resistance to first-generation EGFR tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, in NSCLC patients with activating EGFR mutations [35]. Here, EGFR is linked to non-small cell lung carcinoma.